Delord, Jean-Pierre <br/><br/>
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic   [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2017 
 - 5339-5348 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-2923  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Disease Models, Animal<br/>Drug Evaluation, Preclinical<br/>Drug Monitoring<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Maximum Tolerated Dose<br/>Melanoma--drug therapy<br/>Mice<br/>Molecular Targeted Therapy<br/>Mutation<br/>Neoplasm Staging<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>Xenograft Model Antitumor Assays